, Tracking Stock Market Picks
Enter Symbol:
Alkermes, Inc. (ALKS) [hlAlert]

up 41.95 %

Alkermes, Inc. (ALKS) upgraded to Buy with price target $61 by Mizuho

Posted on: Thursday,  Apr 10, 2014  12:00 AM ET by Mizuho

Mizuho rated Buy Alkermes, Inc. (NASDAQ: ALKS) on 04/10/2014, when the stock price was $43.09. Since
then, Alkermes, Inc. has gained 41.96% as of 01/21/2016's recent price of $61.17.
If you would have followed this Mizuho's recommendation on ALKS, you would have gained 41.95% of your investment in 651 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/31/2014 12:00 AM Buy
42.76 59.00
as of 10/17/2014
1 Week up  7.08 %
1 Month down  -4.64 %
3 Months down  -2.95 %
1 YTD up  0.74 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/10/2014 12:00 AM Buy
43.09 61.00
2/28/2014 8:25 AM Hold
48.67 56.00
11/1/2013 8:25 AM Hold
35.38 33.00
4/18/2013 8:25 AM Hold
29.49 26.00
11/16/2012 8:25 AM Buy
18.83 27.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy